Indivior Pharmaceuticals (INDV) Current Leases (2021 - 2026)

Indivior Pharmaceuticals' Current Leases history runs 6 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Current Leases fell 18.18% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (down 18.18% YoY), while the FY2025 annual figure was $10.0 million, changed 0.0% from the prior year.
• Current Leases was $9.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $10.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $11.0 million in Q1 2025 to a low of $8.0 million in Q4 2022.
• Historically, Current Leases has averaged $9.8 million across 5 years, with a median of $10.0 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Leases advanced 12.5% in 2023, then decreased 18.18% in 2026.
• A 5-year view of Current Leases shows it stood at $8.0 million in 2022, then rose by 12.5% to $9.0 million in 2023, then gained by 11.11% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then fell by 10.0% to $9.0 million in 2026.
• The last three Current Leases figures came in at $9.0 million (Q1 2026), $10.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.